A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943
Completed · Phase 1 · NCT06313528
Conditions: Obesity
At a glance
- Research payments reported, 2025
- $5.9M
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 85
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3437943 (drug), Placebo (other)
- Dates
- Started 2024-03-20; completion 2025-08-26
- Results posted
- Not yet
The main purpose of the study is to look at the effect of the study drug compared to placebo on calorie intake, energy metabolism, and appetite. The study will last up to 6 months and may include up to 20 visits.
From ClinicalTrials.gov, last updated 2025-09-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $5.9M in research payments for this study in 2025 (5 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Richard E. Pratley, MD Endocrinology & Diabetes · Orlando, FL
- Laurel Mayer, MD Psychiatry · New York, NY
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Adventhealth Orlando, FL $5.7M
- Trustees of Columbia Univ in The City of Ny $216,125
- $228
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.